Screener
Edgewise Therapeutics, Inc. EWTX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $42,651 | $36,757 |
| General and administrative | 11,464 | 9,202 |
| Total operating expenses | 54,115 | 45,959 |
| Loss from operations | (54,115) | (45,959) |
| Other income | ||
| Interest income | 5,102 | 5,161 |
| Total other income | 5,102 | 5,161 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s total operating expenses?
- Edgewise Therapeutics, Inc. (EWTX) reported total operating expenses of $54.12M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s total operating expenses changed year-over-year?
- Edgewise Therapeutics, Inc.'s total operating expenses increased by 17.7% year-over-year, from $45.96M to $54.12M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s total operating expenses has grown at a 45.1% compound annual growth rate (CAGR), from $43.22M to $191.41M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Edgewise Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude